Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection

Gynecologic Oncology

Volumn 144, Issue 2, 2017, Pages 241-242

  Dizon, Don S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL DISEASE; ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; COMORBIDITY; CYTOREDUCTIVE SURGERY; DRUG ADMINISTRATION ROUTE; EDITORIAL; HUMAN; MORBIDITY; MORTALITY; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STATISTICAL SIGNIFICANCE; SURGICAL RISK; FEMALE; GYNECOLOGY; HEALTH CARE QUALITY; NEOADJUVANT THERAPY; ONCOLOGY; OVARY TUMOR; PROGNOSIS; SURGICAL ONCOLOGY;

ANTINEOPLASTIC AGENTS; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PATIENT SELECTION; PROGNOSIS; QUALITY OF HEALTH CARE; SURGICAL ONCOLOGY;

EID: 85008425376     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.12.020     Document Type: Editorial

References (9)

1. [1] Earle, C.C., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 (2006), 172–180.
2. [2] Chang, S.-J., Hodeib, M., Chang, J., Bristow, R.E., Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol., 2013, 10.1016/j.ygyno.2013.05.040.
3. [3] Wright, A.A., et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol. Oncol. 143 (2016), 3–15.
4. [4] Kehoe, S., et al. Chemotherapy or Upfront Surgery for Newly Diagnosed Advanced Ovarian Cancer: Results From the MRC CHORUS Trial. 2013.
5. [5] Chi, D.S., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114 (2009), 26–31.
6. [6] von Minckwitz, G., et al. Response-guided neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31 (2013), 3623–3630.
7. [7] Mackay, H.J., et al. OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) Versus Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery in Epithelial Ovarian Cancer (EOC). 2016.
8. [8] Armstrong, D.K., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006), 34–43.
9. [9] Hess, L.M., et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int. J. Gynecol. Cancer 17 (2007), 561–570.